Drugs / BR6002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05959486 | Jul → Aug 2023 | peptic ulcer disease | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05959499 | Jul → Sep 2023 | peptic ulcer disease | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BR6002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05959486 ↗ |